480 related articles for article (PubMed ID: 26965523)
1. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
2. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
[TBL] [Abstract][Full Text] [Related]
3. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
Holzinger A; Abken H
Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
[No Abstract] [Full Text] [Related]
4. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor.
Krug C; Wiesinger M; Abken H; Schuler-Thurner B; Schuler G; Dörrie J; Schaft N
Cancer Immunol Immunother; 2014 Oct; 63(10):999-1008. PubMed ID: 24938475
[TBL] [Abstract][Full Text] [Related]
5. Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology.
Rotolo A; Atherton MJ
Clin Cancer Res; 2024 Jun; 30(11):2359-2369. PubMed ID: 38573683
[TBL] [Abstract][Full Text] [Related]
6. Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
Pang Y; Hou X; Yang C; Liu Y; Jiang G
Mol Cancer; 2018 May; 17(1):91. PubMed ID: 29769134
[TBL] [Abstract][Full Text] [Related]
7. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
[TBL] [Abstract][Full Text] [Related]
8. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
[TBL] [Abstract][Full Text] [Related]
9. Prospects and challenges of CAR-T in the treatment of ovarian cancer.
Chen B; Liu J
Int Immunopharmacol; 2024 May; 133():112112. PubMed ID: 38640714
[TBL] [Abstract][Full Text] [Related]
10. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
Maus MV; Haas AR; Beatty GL; Albelda SM; Levine BL; Liu X; Zhao Y; Kalos M; June CH
Cancer Immunol Res; 2013 Jul; 1(1):26-31. PubMed ID: 24777247
[TBL] [Abstract][Full Text] [Related]
11. Overcoming the toxicity hurdles of genetically targeted T cells.
Casucci M; Hawkins RE; Dotti G; Bondanza A
Cancer Immunol Immunother; 2015 Jan; 64(1):123-30. PubMed ID: 25488419
[TBL] [Abstract][Full Text] [Related]
12. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.
Nielsen AY; Ormhøj M; Traynor S; Gjerstorff MF
Cancer Immunol Immunother; 2020 Nov; 69(11):2169-2178. PubMed ID: 32648166
[TBL] [Abstract][Full Text] [Related]
13. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs.
Hadiloo K; Taremi S; Safa SH; Amidifar S; Esmaeilzadeh A
Pharmacol Res; 2024 May; 203():107158. PubMed ID: 38599467
[TBL] [Abstract][Full Text] [Related]
14. The growing world of CAR T cell trials: a systematic review.
Holzinger A; Barden M; Abken H
Cancer Immunol Immunother; 2016 Dec; 65(12):1433-1450. PubMed ID: 27613725
[TBL] [Abstract][Full Text] [Related]
15. CAR T-Cell Production Using Nonviral Approaches.
Lukjanov V; Koutná I; Šimara P
J Immunol Res; 2021; 2021():6644685. PubMed ID: 33855089
[TBL] [Abstract][Full Text] [Related]
16. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer.
Chmielewski M; Abken H
Cancer Immunol Immunother; 2012 Aug; 61(8):1269-77. PubMed ID: 22274776
[TBL] [Abstract][Full Text] [Related]
17. An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies.
Chen L; Dong L; Ma Y; Wang J; Qiao D; Tian G; Wang M
BMC Immunol; 2021 Sep; 22(1):65. PubMed ID: 34583647
[TBL] [Abstract][Full Text] [Related]
18. Three recent breakthroughs in CAR T cells for the treatment of glioblastoma: Is it the light at the end of the tunnel?
Lowenstein PR; Varela ML; Castro MG
Mol Ther; 2024 May; 32(5):1187-1189. PubMed ID: 38631354
[No Abstract] [Full Text] [Related]
19. Nano-optogenetic immunotherapy.
Huang K; Liu X; Han G; Zhou Y
Clin Transl Med; 2022 Sep; 12(9):e1020. PubMed ID: 36101937
[TBL] [Abstract][Full Text] [Related]
20. Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.
Gomes-Silva D; Ramos CA
Biotechnol J; 2018 Feb; 13(2):. PubMed ID: 28960810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
